Therefore, the data are insufficient to enable meaningful interpretation in terms of the relation between CYP2C19 phenotype and IPA in patients in the prasugrel groups versus those in the clopidogrel group. This evidence concerns the gene CYP2C19 and Ito hypomelanosis.